Why your weight is not dropping on Mounjaro — and what actually helps

What SURMOUNT-1 actually shows about the pace of weight loss

The SURMOUNT-1 trial (which randomised 2,539 adults with obesity over 72 weeks and is published in the New England Journal of Medicine) recorded average reductions of around 20–21% of body weight at the 15mg maintenance dose. That figure is an average across the full trial period. It does not describe a smooth weekly decline.

Participants in large-scale trials routinely report weeks where the scales barely shift, followed by weeks where they move quickly. The body does not reduce fat at a constant rate. Early weight change often reflects fluid shifts, gut content and glycogen depletion rather than adipose tissue. Once those early fluctuations settle, the rate of fat loss can look slower on the scales than it feels in terms of clothes fit or energy.

There is a common misconception that if the number on the scales has not changed in a fortnight, the medicine is not working. In practice, body composition can shift positively (less visceral fat, better metabolic markers) while the scales lag behind. That does not make a genuine multi-week plateau something to ignore, but it does mean the first two or three weeks of slower movement rarely warrant concern.

The NICE appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing treatment should be reviewed. That threshold matters: it is six months at a therapeutic dose, not six weeks at 2.5mg.

Why the starting dose feels like nothing is happening

Mounjaro's licensed schedule begins at 2.5mg for at least four weeks. The first pen's job is to let your system adjust, nausea, reflux and other gastrointestinal effects are most likely to surface early, and the starter dose reduces the chance of them being severe enough to stop treatment. It is not designed to deliver the maximum appetite-suppression effect.

Many people find that meaningful appetite reduction only becomes noticeable from 5mg or 7.5mg onward. If you are reading this in your first month and wondering why nothing has shifted, that is worth knowing. The trajectory at 2.5mg is not predictive of your trajectory at higher doses.

Our page on when Mounjaro weight loss drops covers the timeline in more detail. Titration pace is set by your prescriber based on tolerability and response, changing it without clinical input risks either pushing through side effects too fast or staying at a sub-therapeutic dose too long.

Other reasons weight stalls: what clinical evidence points to

Several factors beyond the dose itself can slow or stall weight loss on tirzepatide. Dietary patterns matter even when appetite is reduced: if calorie intake has not shifted meaningfully, or protein is low and muscle loss has crept in, the scales reflect that. Tirzepatide slows gastric emptying, which extends fullness, but it does not remove the need for a modest energy deficit.

Sleep quality and chronic stress affect cortisol and hunger hormones in ways that can partially offset GLP-1 and GIP signalling. Metabolic adaptation (the body reducing its resting energy expenditure in response to weight loss) is a documented phenomenon that affects longer-term weight loss regardless of the medicine involved. Strength-based activity helps preserve lean mass during weight loss and keeps metabolic rate from dropping as sharply.

It is also worth noting that some medicines interact with tirzepatide's effects. Oral contraceptives may have reduced absorption during the first four weeks of treatment and for four weeks after each dose increase, as the NHS England guidance on weight-management injections explains, relevant because hormonal changes can affect water retention and weight readings too.

For a broader look at what shapes outcomes, the Mounjaro and weight page pulls together the clinical picture.

When a genuine plateau needs clinical attention

A week or two of slower movement is normal. A plateau of six weeks or more at a stable therapeutic dose, with no change in measurements, energy or clothing fit, is a signal to talk to a prescriber. The right response is rarely stopping treatment (that question is explored separately on our stopping Mounjaro page) but it may mean a dose review, a closer look at dietary patterns, or ruling out a medical reason for resistance.

If you started on tirzepatide elsewhere and are wondering whether a transfer to a clinically supervised service makes sense, our guide for people who have not lost weight on Mounjaro addresses that directly. And for anyone yet to start treatment, how Mounjaro prescriptions work in the UK explains the clinical process from the beginning.

The tirzepatide overview covers the mechanism and evidence base if you want to understand how the medicine works before deciding your next step.

If a slow response is making you question whether treatment is right for you, speaking to a prescriber is a more useful step than adjusting anything yourself. Speak to our prescribers through a free consultation, a real clinician reads your answers the same day.